Difference between revisions of "Classical Hodgkin lymphoma"
Jump to navigation
Jump to search
(Created page with "==ABVD ([[Doxorubicin (Adriamycin), Bleomycin (Blenoxane), Vinblastine (Velban), Dacarbazine (DTIC) (stage I-IV Hodgkin lymphoma)== *Doxorubicin (Adriamycin) 25 mg/m2...") |
|||
| Line 1: | Line 1: | ||
| − | ==ABVD ([[Doxorubicin (Adriamycin), [[Bleomycin (Blenoxane)]], [[Vinblastine (Velban)]], [[Dacarbazine (DTIC)]] (stage I-IV Hodgkin lymphoma)== | + | ==ABVD ([[Doxorubicin (Adriamycin)]], [[Bleomycin (Blenoxane)]], [[Vinblastine (Velban)]], [[Dacarbazine (DTIC)]] (stage I-IV Hodgkin lymphoma)== |
*Doxorubicin (Adriamycin) 25 mg/m2 IV D1 & 15 | *Doxorubicin (Adriamycin) 25 mg/m2 IV D1 & 15 | ||
*Bleomycin (Blenoxane) 10 units/m2 IV D1 & 15 (1 unit test dose with cycle 1 doses, 60 minutes prior to remainder of full dose) | *Bleomycin (Blenoxane) 10 units/m2 IV D1 & 15 (1 unit test dose with cycle 1 doses, 60 minutes prior to remainder of full dose) | ||
| Line 22: | Line 22: | ||
===References=== | ===References=== | ||
| − | [http://www.nejm.org/doi/pdf/10.1056/NEJM199211193272102] | + | *[http://www.nejm.org/doi/pdf/10.1056/NEJM199211193272102 Canellos GP, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992 Nov 19;327(21):1478-84.] |
| − | [http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31090 Gianni AM et al. Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced Hodgkin's lymphoma (HL): a randomized trial of the Michelangelo, GITIL and IIL cooperative groups. 2008 ASCO annual meeting. Abstract 8506] | + | *[http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31090 Gianni AM et al. Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced Hodgkin's lymphoma (HL): a randomized trial of the Michelangelo, GITIL and IIL cooperative groups. 2008 ASCO annual meeting. Abstract 8506] |
| − | [http://jco.ascopubs.org/cgi/content/abstract/22/14/2835 Bonadonna G et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 2004; 22:2835] | + | *[http://jco.ascopubs.org/cgi/content/abstract/22/14/2835 Bonadonna G et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 2004; 22:2835] |
| − | [http://www.jco.org/cgi/content/abstract/11/11/2258 Carde, P et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: The H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1993; 11:2258] | + | *[http://www.jco.org/cgi/content/abstract/11/11/2258 Carde, P et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: The H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1993; 11:2258] |
| − | [http://content.nejm.org/cgi/content/abstract/327/21/1478?firstpage=1478&volume=327&sendit=GO&searchid=1&FIRSTINDEX=0&volume=327&firstpage=1478&resourcetype=HWCIT Canellos GP et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Eng J Med 1992; 327:1478] | + | *[http://content.nejm.org/cgi/content/abstract/327/21/1478?firstpage=1478&volume=327&sendit=GO&searchid=1&FIRSTINDEX=0&volume=327&firstpage=1478&resourcetype=HWCIT Canellos GP et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Eng J Med 1992; 327:1478] |
| − | [http://jco.ascopubs.org/cgi/content/abstract/25/23/3495 Engert A et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: Final results of the GHSG HD7 trial. J Clin Oncol 2007; 25:3495] | + | *[http://jco.ascopubs.org/cgi/content/abstract/25/23/3495 Engert A et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: Final results of the GHSG HD7 trial. J Clin Oncol 2007; 25:3495] |
==Stanford V== | ==Stanford V== | ||
Revision as of 01:48, 14 November 2011
ABVD (Doxorubicin (Adriamycin), Bleomycin (Blenoxane), Vinblastine (Velban), Dacarbazine (DTIC) (stage I-IV Hodgkin lymphoma)
- Doxorubicin (Adriamycin) 25 mg/m2 IV D1 & 15
- Bleomycin (Blenoxane) 10 units/m2 IV D1 & 15 (1 unit test dose with cycle 1 doses, 60 minutes prior to remainder of full dose)
- Vinblastine (Velban) 6 mg/m2 IV D1 & 15
- Dacarbazine (DTIC) 375 mg/m2
Q28days x 4-6 cycles based on stage, response, and concurrent therapy.
Supportive medications
Antiemetic risk: high
- Acetaminophen 650 mg PO, 30 minutes prior to chemotherapy.
- Aprepitant (Emend) 125 mg PO on D1 prior to chemotherapy, 80mg PO on D2 & 3
- Ondansetron (Zofran) 8 mg PO, 30 minutes prior to chemotherapy on D1, daily on D2-3
- Dexamethasone 4 mg PO BID on D1-3
- Diphendyramine (Benadryl) 25 mg PO on D1 prior to chemotherapy
Supportive Hydration
- 500 ml NS at KVO rate. Use as running IV for chemotherapy infusion.
Pretreatment monitoring parameters
- CBC with diff, liver function tests, pulmonary function tests with DLCO
References
- Canellos GP, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992 Nov 19;327(21):1478-84.
- Gianni AM et al. Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced Hodgkin's lymphoma (HL): a randomized trial of the Michelangelo, GITIL and IIL cooperative groups. 2008 ASCO annual meeting. Abstract 8506
- Bonadonna G et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 2004; 22:2835
- Carde, P et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: The H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1993; 11:2258
- Canellos GP et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Eng J Med 1992; 327:1478
- Engert A et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: Final results of the GHSG HD7 trial. J Clin Oncol 2007; 25:3495